Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (2606)	6/25/1999 12:02:00 AM
From: jackie	Read Replies (1) \| Respond to of 4676

Mike, I feel somewhat remiss it commenting on Remicade. A few weeks ago I had the opportunity to speak with some of the staff at a local GI clinic here in town. I started talking about Isis and Crohn's disease and they brought up Remicade. All in all, they were thrilled to have something to use for treating patients with severe cases besides steroids. However, they pointed out it was extremely expensive and the long term effects are simply unknown. It seems, in their minds for sure, to be a product with a very narrow segment of the target population of Chrohn's disease sufferers. None commented on the halt in steroid use. It seemed it was worth a try even if it was not a long term solution to the victim's condition. Desperation? Hopeful desperation? So, for at least this clinic, the jury is still out on the long term effectiveness of Remicade. It certainly supports your suggestion of optimism for Isis 2302. I'm sure these people would welcome another treatment option. I was going to mention this experience on this thread, but one thing or another kept coming up. I'm glad you mentioned this as it reminded me of my original intentions. Regards, Jack Simmons